Survey announced for long-term investors

An investigation on behalf of investors in NeoGenomics, Inc. (NASDAQ: NEO) stock into potential wrongdoing at NeoGenomics, Inc.

An investigation has been announced into possible breaches of fiduciary duties by certain officers and directors of NeoGenomics, Inc.

Investors who have purchased shares of NeoGenomics, Inc. (NASDAQ: NEO) have certain options and should contact the Shareholders Foundation at [email protected] or call +1(858) 779 – 1554.

The investigation by a law firm focuses on whether certain directors of NeoGenomics, Inc. breached their fiduciary duties and caused harm to the company and its shareholders.

NeoGenomics, Inc. reported that its annual total revenue increased from $408.83 million in 2019 to $444.44 million in 2020, and its net income increased from $8 million in 2019 to 4.17 million dollars in 2020.

On November 4, 2021, NeoGenomics, Inc. released its third quarter financial results. Additionally, NeoGenomics announced an “Executive Team Transition”. NeoGenomics said its current chief financial officer has led the company through multiple acquisitions, financing events and guided the company through financial challenges associated with the global COVID-19 pandemic and will be named chief sustainability officer and effective January 1, 2022. NeoGenomics said William Bonello, who is currently president of NeoGenomics’ IT division, will be appointed chief financial officer effective January 1, 2022.

On March 28, 2022, NeoGenomics, Inc. announced that its CEO “will step down as CEO and member of the Board of Directors, effective immediately.” NeoGenomics, Inc. also announced that it “expects first-quarter 2022 revenue to be below the low end of its prior guidance of $118-120 million and that first-quarter 2022 EBITDA below the low range of its earlier guidance of ($15)-$(12) million.” NeoGenomics revealed that “[t]The larger than expected EBITDA loss was primarily due to a higher than expected cost of goods sold for clinical services” and that it “withdrew its 2022 annual financial guidance issued on February 23, 2022”.

Shares of NeoGenomics, Inc. (NASDAQ: NEO) fell from $47.13 per share on November 1, 2021 to $9.12 per share on May 6, 2022.

Those who have purchased NeoGenomics, Inc. (NASDAQ: NEO) stock have certain options and should contact the Shareholders Foundation.

Christopher Clausen
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Office 423
San Diego, CA 92108
Such. : +1-(858)-779-1554
Email: [email protected]

About the Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claims filing service and investor advocacy group that researches shareholder issues and advises investors of shareholder lawsuits. securities, regulations, judgments and other legal news related to the stock / financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support and assistance to each shareholder. The Shareholders Foundation, Inc. is not a law firm. The cases, investigations and/or settlements referenced are not filed/initiated/reached and/or related to the Shareholders Foundation. The information is provided as a public service. It is not legal advice and should not be relied upon.

This press release was published on openPR.

Previous Global Healthcare Payment Services Market Snapshot to 2030 - Featuring Cognizant, Accenture, and Genpact, Among Others -
Next The global healthcare payer services industry is